Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Sanofi SA — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $84.63, while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| ROBO | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $52.34 |
52-Week Low | $62.34 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $84.79, up 1.59% with strong bullish technical signals from moving averages. The robotics ETF benefits from AI infrastructure expansion and recent sector momentum, though key valuation metrics remain undisclosed. Recent news highlights robotics as the next phase of AI investment beyond semiconductors, with thematic ETF comparisons favoring ROBO's diversified approach to automation exposure.
Outlook remains positive given structural AI adoption tailwinds, but elevated RSI levels suggest near-term consolidation risk. The ETF's 79-stock global portfolio offers diversified robotics exposure, though cyclical industrial dependencies and valuation concerns after recent rallies present balanced risk-reward dynamics for long-term investors.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
